



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

29<sup>th</sup> May, 2023

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclosed herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref: PR/01/2023-24**

**29<sup>th</sup> May, 2023**

### **NATCO records INR 2811.7 Crore consolidated revenue and INR 715.3 Crore of Profit after tax for the year ended March 31<sup>st</sup>, 2023**

*Hyderabad, 29<sup>th</sup>May, 2023*

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 2811.7 Crore for the year ended on 31<sup>st</sup> March, 2023, as against INR 2043.8 Crore for the last year, reflecting 37.6% growth. The net profit for the period, on a consolidated basis, was INR 715.3 Crore, as against INR 170.0 Crore last year.

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years.

For the fourth quarter (Q4) ended March 31<sup>st</sup>, 2023, the company recorded a net revenue of INR 926.9 Crore, on a consolidated basis, as against INR 610.6 Crore during Q4, FY 2022. The profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.

Segmental Revenue Split (All Figures in INR Crore)-

Segment	Revenue, Q4 FY23	Revenue, Full Year FY23
API	72.8	210.3
Formulations, Domestic	91.8	374.9
Formulations, Exports (incl. Profit Share & Foreign Subs)	709.2	2063.2
Other Operating income & non-operating income	26.1	122.4
Crop Health Sciences (CHS)	27.0	40.9

For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer